Doxorubicin Transdrug(R): Significant Increased Survival Rate In Patients With Advanced Hepatocellular Carcinoma … (Medical News Today)

BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces positive survival data in its phase II clinical trial with doxorubicin Transdrug® in patients with advanced hepatocellular carcinoma (primary liver cancer). Doxorubicin Transdrug®, a treatment presented in the form of nanoparticles delivered via hepatic intra …
(read here…)

Related items

• Phase II clinical trial results of Doxorubicin Transdrug announced (News-Medical-Net)
• Doxorubicin Transdrug®: Significant increased survival rate in patients with advanced hepatocellular carcinoma treated … (Business Wire via Yahoo! Finance)
• Researchers use nanotechnology to burst cancer cells (IT World)
• Prostate Cancer Recurrence Detected Early in Nanosphere Test (Bloomberg)
• Cancer Therapeutics and Nanotherapies sign letter of intent (News-Medical-Net)

Tags: aids patients, BioAlliance, bioalliance pharma, cancer, doxorubicin, hepatocellular carcinoma, liver cancer, nano, nanoparticle, nanoparticles, nanotech, nanotechnology, primary liver cancer, survival data, Technology, Transdrug, treatment

This entry was posted on Thursday, December 10th, 2009 at 10:51 pm and is filed under Technology.